JPWO2019067503A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019067503A5 JPWO2019067503A5 JP2020515000A JP2020515000A JPWO2019067503A5 JP WO2019067503 A5 JPWO2019067503 A5 JP WO2019067503A5 JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020515000 A JP2020515000 A JP 2020515000A JP WO2019067503 A5 JPWO2019067503 A5 JP WO2019067503A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- heteroaryl
- aryl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 158
- 125000001072 heteroaryl group Chemical group 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 58
- 150000002367 halogens Chemical class 0.000 claims description 58
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 52
- 125000003342 alkenyl group Chemical group 0.000 claims description 47
- 125000001188 haloalkyl group Chemical group 0.000 claims description 42
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000000304 alkynyl group Chemical group 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- -1 -NR 7 R 8 Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical group [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 10
- 208000034578 Multiple myelomas Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 101150020913 USP7 gene Proteins 0.000 claims description 7
- 102000052151 Ubiquitin-Specific Peptidase 7 Human genes 0.000 claims description 7
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 claims description 7
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 3
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 230000002917 arthritic effect Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000023589 ischemic disease Diseases 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000006958 oropharynx cancer Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 238000000034 method Methods 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108091008648 NR7C Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023142246A JP2023164918A (ja) | 2017-09-26 | 2023-09-01 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563375P | 2017-09-26 | 2017-09-26 | |
| US62/563,375 | 2017-09-26 | ||
| PCT/US2018/052797 WO2019067503A1 (en) | 2017-09-26 | 2018-09-26 | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023142246A Division JP2023164918A (ja) | 2017-09-26 | 2023-09-01 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020535124A JP2020535124A (ja) | 2020-12-03 |
| JP2020535124A5 JP2020535124A5 (enExample) | 2021-11-11 |
| JPWO2019067503A5 true JPWO2019067503A5 (enExample) | 2023-09-12 |
| JP7402792B2 JP7402792B2 (ja) | 2023-12-21 |
Family
ID=65903565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515000A Active JP7402792B2 (ja) | 2017-09-26 | 2018-09-26 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
| JP2023142246A Pending JP2023164918A (ja) | 2017-09-26 | 2023-09-01 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023142246A Pending JP2023164918A (ja) | 2017-09-26 | 2023-09-01 | 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11465983B2 (enExample) |
| EP (1) | EP3687537A4 (enExample) |
| JP (2) | JP7402792B2 (enExample) |
| AU (1) | AU2018342089B2 (enExample) |
| CA (1) | CA3072353A1 (enExample) |
| WO (1) | WO2019067503A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067503A1 (en) | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| AU2019368263B2 (en) * | 2018-10-22 | 2025-01-23 | Dana-Farber Cancer Institute, Inc. | USP7 inhibition |
| KR20210100127A (ko) * | 2018-12-06 | 2021-08-13 | 알막 디스커버리 리미티드 | 치료용 usp19 억제제 |
| AU2020267757B2 (en) * | 2019-05-06 | 2025-03-27 | Valo Health, Inc. | Inhibiting USP19 |
| US20230087388A1 (en) | 2020-02-28 | 2023-03-23 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3344099A (en) | 1998-04-17 | 1999-11-08 | Kyowa Hakko Kogyo Co. Ltd. | Analgetic agent |
| US7501417B2 (en) | 2002-03-13 | 2009-03-10 | Janssen Pharmaceutica, N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| CA2656825C (en) * | 2006-06-22 | 2013-12-10 | Prana Biotechnology Limited | Method of treatment and agents useful for same |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| HK1248222A1 (zh) * | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂 |
| JP2018504432A (ja) * | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| WO2019067503A1 (en) | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| AU2019368263B2 (en) | 2018-10-22 | 2025-01-23 | Dana-Farber Cancer Institute, Inc. | USP7 inhibition |
-
2018
- 2018-09-26 WO PCT/US2018/052797 patent/WO2019067503A1/en not_active Ceased
- 2018-09-26 JP JP2020515000A patent/JP7402792B2/ja active Active
- 2018-09-26 US US16/650,727 patent/US11465983B2/en active Active
- 2018-09-26 CA CA3072353A patent/CA3072353A1/en active Pending
- 2018-09-26 AU AU2018342089A patent/AU2018342089B2/en active Active
- 2018-09-26 EP EP18862773.1A patent/EP3687537A4/en active Pending
-
2022
- 2022-09-02 US US17/902,512 patent/US20230265070A1/en active Pending
-
2023
- 2023-09-01 JP JP2023142246A patent/JP2023164918A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023164918A5 (enExample) | ||
| JP2020535124A5 (enExample) | ||
| JP2016500107A5 (ja) | グルタミナーゼ阻害剤およびその使用方法 | |
| JP2019529490A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2017531688A5 (enExample) | ||
| JP2019507130A5 (enExample) | ||
| JP2008528447A5 (enExample) | ||
| BRPI0413991B1 (pt) | composto ativador de ppar e composição farmacêutica contendo o mesmo | |
| JP2017504576A5 (enExample) | ||
| JP2014520108A5 (enExample) | ||
| JPWO2019067503A5 (enExample) | ||
| JPWO2022036297A5 (enExample) | ||
| JPWO2022251502A5 (enExample) | ||
| JPWO2021133896A5 (enExample) | ||
| JPWO2019031470A1 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP2020533319A5 (enExample) | ||
| JP2004517088A5 (enExample) | ||
| JPWO2020033490A5 (enExample) | ||
| JPWO2020033520A5 (enExample) | ||
| NZ586955A (en) | Novel process for the preparation of vorinostat | |
| JP2013544880A5 (enExample) | ||
| JPWO2023072257A5 (enExample) | ||
| JPWO2020264509A5 (enExample) |